Cable Hill Partners LLC Sells 80 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Cable Hill Partners LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,555 shares of the medical research company’s stock after selling 80 shares during the quarter. Cable Hill Partners LLC’s holdings in Thermo Fisher Scientific were worth $724,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in Thermo Fisher Scientific by 2.2% during the fourth quarter. BlackRock Inc. now owns 29,504,221 shares of the medical research company’s stock worth $13,742,475,000 after acquiring an additional 624,512 shares during the period. FMR LLC increased its position in Thermo Fisher Scientific by 5.6% during the fourth quarter. FMR LLC now owns 13,022,987 shares of the medical research company’s stock worth $6,065,847,000 after acquiring an additional 686,768 shares during the period. C WorldWide Group Holding A S increased its position in Thermo Fisher Scientific by 1.8% during the fourth quarter. C WorldWide Group Holding A S now owns 1,973,894 shares of the medical research company’s stock worth $919,400,000 after acquiring an additional 35,261 shares during the period. Alps Advisors Inc. increased its position in Thermo Fisher Scientific by 287,808.7% during the third quarter. Alps Advisors Inc. now owns 1,954,900 shares of the medical research company’s stock worth $1,634,000 after acquiring an additional 1,954,221 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Thermo Fisher Scientific by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,915,477 shares of the medical research company’s stock worth $845,722,000 after acquiring an additional 48,950 shares during the period. 87.17% of the stock is currently owned by institutional investors.

A number of equities analysts recently issued reports on the stock. BTIG Research boosted their target price on shares of Thermo Fisher Scientific from $540.00 to $590.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. Credit Suisse Group lifted their price target on shares of Thermo Fisher Scientific from $556.00 to $580.00 in a research note on Tuesday, January 12th. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $512.00 to $523.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 2nd. Cowen lifted their price target on shares of Thermo Fisher Scientific from $525.00 to $585.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 2nd. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $550.00 to $500.00 in a research note on Wednesday, December 16th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $527.47.

Shares of NYSE:TMO traded down $8.29 on Tuesday, hitting $454.99. The stock had a trading volume of 17,800 shares, compared to its average volume of 1,767,478. The firm’s 50 day moving average price is $500.86 and its 200-day moving average price is $464.08. The company has a market capitalization of $180.33 billion, a price-to-earnings ratio of 37.97, a price-to-earnings-growth ratio of 1.40 and a beta of 0.85. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.31 and a current ratio of 2.93. Thermo Fisher Scientific Inc. has a twelve month low of $250.21 and a twelve month high of $532.57.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Sunday, January 31st. The medical research company reported $7.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $6.56 by $0.53. The business had revenue of $10.55 billion for the quarter, compared to the consensus estimate of $9.53 billion. Thermo Fisher Scientific had a net margin of 17.12% and a return on equity of 21.35%. The firm’s quarterly revenue was up 54.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.55 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 19.03 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback program on Thursday, November 5th that authorizes the company to buyback $2.50 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.

In related news, COO Mark Stevenson sold 14,113 shares of the company’s stock in a transaction dated Friday, December 4th. The shares were sold at an average price of $476.46, for a total transaction of $6,724,279.98. Following the transaction, the chief operating officer now owns 58,005 shares in the company, valued at approximately $27,637,062.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.44% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.

Read More: Calculate Your Return on Investment (ROI)

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.